Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828593 | 1.00 | CA2 (0.50) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1828512 | 0.90 | SMN1; SMN2 (0.51) | CA2CA1SMN1; SMN2PRMT1KMT2A | |
| SCHEMBL1828515 | 0.90 | SMN1; SMN2 (0.51) | CA2CA1SMN1; SMN2PRMT1KMT2A | |
| SCHEMBL1831544 | 0.88 | KMT2A (0.53) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1828432 | 0.88 | CA2 (0.50) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1829475 | 0.88 | KMT2A (0.54) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1830012 | 0.88 | SMN1; SMN2 (0.53) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1830014 | 0.88 | SMN1; SMN2 (0.53) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1832501 | 0.88 | KMT2A (0.53) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1828430 | 0.88 | CA2 (0.50) | CA2F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320520-B1 | SULFONYLGUANIDINE | GRUENENTHAL GMBH (DE) | 2011-05-11 | — | — | EP | claimed |
| US-7671074-B2 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2010-03-02 | — | — | US | claimed |
| US-20080085900-A1 | SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GRUENENTHAL GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| US-20030225084-A1 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2003-12-04 | — | — | US | claimed |
| EP-1320520-A1 | SULFONYLGUANIDINE | Grünenthal GmbH (DE) | 2003-06-25 | — | — | EP | claimed |
| WO-2002030881-A1 | SULFONYLGUANIDINE | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| EP-1320520-B1 | SULFONYLGUANIDINE | GRUENENTHAL GMBH (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-7671074-B2 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-7671074-B2 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-7671074-B2 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-20080085900-A1 | SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GRUENENTHAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20080085900-A1 | SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GRUENENTHAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20080085900-A1 | SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GRUENENTHAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20030225084-A1 | Sulfonylguanidine compounds and pharmaceutical uses thereof | GRUENENTHAL GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1320520-A1 | SULFONYLGUANIDINE | Grünenthal GmbH (DE) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002030881-A1 | SULFONYLGUANIDINE | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085900-A1 | SULFONYLGUANIDINE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | CACNA1G, CACNA1I, CACNA1A | CA2 401/4885F2 2763/4885PRSS1 1446/4885 |
| US-20030225084-A1 | Sulfonylguanidine compounds and pharmaceutical uses thereof | CACNA1G, CACNA1I, CACNA1A | CA2 401/4885F2 2763/4885PRSS1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.